Skip to main content
. Author manuscript; available in PMC: 2011 Jul 15.
Published in final edited form as: Clin Cancer Res. 2010 May 12;16(14):3786–3794. doi: 10.1158/1078-0432.CCR-10-0547

Table 5.

Mean ± SD pharmacokinetic parameters for plasma FU

FU maintenance dose (mg/m2) Vorinostat (mg) Css (µg/mL) Cmax (µg/mL) AUC (µg h/mL)
2,400 600 twice daily 0.271 ± 0.014 13.0 ± 3.17 24.8 ± 3.51
2,400 — 0.347 ± 0.092 11.2 ± 5.55 21.8 ± 9.68
2,400 1,700 once daily 0.398 ± 0.106 14.2 ± 2.87 27.2 ± 5.11
2,400 — 0.439 ± 0.172 17.3 ± 2.97 29.9 ± 6.66

NOTE: Data were compared by paired Student's t-test. The difference in Cmax pre- and post-vorinostat on the 1,700 once-daily dose level was the only statistically significant finding (P < 0.05).